Scancell Share Discussion Threads

[tosh123] 31/1/2019 09:27

ONW,
as discussed last week, the bunny needs to come quickly and be a big one.

There is nothing in the RNS that fills me with confidence, and i mean nothing, even this statement actually means nothing, if you read it properly ... " Scancell and its collaboration partners remain committed to the ultimate objective of eliminating tumours by treating patients with such therapeutic vaccine approaches "....

If the relevant companies weren't committed, they wouldn't be in business. Notably though, theres nothing to indicate that Scancell and its blueprint partners, will continue to " collaborate " or any mention of the word " together ", just that everyone is committed.

There has to be a plan B somewhere... and it cant be another raise.

[torquayfan] 31/1/2019 09:27

ONW - ''. . . IP is now beginning to look a little threatened by the somewhat unclear/oft thwarted "strategy" the BOD is pursuing''.

The problem is in the sheer breadth of the science - admittedly Scancell have very many targets in focus now - just one needs to be 'pulled from the hat'.

The science is there but where are the deals ? Agreed . .

[panama7] 31/1/2019 09:25

ONW, best post for ages, far better summary than idiots on the other Channel. This Company is a total shambles, the situation we are in has been brought about by the total mis managaement of a BOD who couldn't care less about their Shareholders whether PI's or II's. How on earth with the position we are in was Goodfellow given a 40% pay rise last year, quite simply that is theft. The only surprise is that he has legged it to France and not the Costa Del Crime.

[oldnotwise] 31/1/2019 09:08

Well, having decided that I'll go with the BOD idea that Data is the key for the rerate of Scancell's somewhat weak share price I'm slightly less relaxed as to where this data's going to come from....
BUT IF we can hang on and keep costs under control let's hope it's not going to be as shaky a ride as the current Cashburn/Delays/SP weakness suggests it might be.
I keep saying I hope that the BOD have got a rabbit to pull from the hat, BUT there's only so many times you can say that!
The adage,"the science will see us through" seems not to be necessarily the correct viewpoint, in that the science (IP) is now beginning to look a little threatened by the somewhat unclear/oft thwarted "strategy" the BOD is pursuing.
We are, in my opinion, beginning to look a little financially vulnerable. How can this be, given the quality of the IP?
I'm not giving up on Scancell, but, for goodness sake, it's not a model of how a company with an (apparently) world beating USP should be performing in a market which is actively looking for companies of this ilk.
AIMO
ATB

[kreature] 31/1/2019 07:30

Is that a 50% increase in losses? Well good luck with that today

How does anyone spend 600,000 a month? Is that the Epson cartridges? I find Canon to be cheaper.

[oldnotwise] 30/1/2019 14:15

Good to see newbies confusing Robin and Richard Goodfellow on historic news hehe :-)
All been seen before...
ATB

[bioking] 30/1/2019 11:09

Faron Pharma (FARN) = Market cap only 17 million / YODA Results & Final Phase 3 results from Japan IMMINENT / Traumakine as orhpan Drug has over $500 million in sales potential / NO approved Drug to date for the treatment of ARDS = 1000% UPSIDE Potential easily


The YODA study will now examine concomitant administration of prednisolone and Traumakine in order to confirm, in vivo, the observed interference of corticosteroids on IFN-beta bioactivity in the INTEREST study and ex vivo lung samples. These YODA results are expected during Q1 2019.

The company continues to await top-line data from the Phase III ARDS trial with Japanese partner Maruishi (JapicCTI-163320) to help determine next steps for Traumakine's development. These data, originally expected before the end of year, are now anticipated by Faron in early 2019.


Faron Pharma confident Traumakine could be ‘very effective’ for ARDS subgroup
[...]

Faron Pharma (LON:FARN) CEO Markku Jalkanen tells Proactive London’s Andrew Scott he's confident their Traumakine drug has the potential to treat around a third of acute respiratory distress syndrome (ARDS) patients in Europe and North America

ARDS is a life-threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu.

Following on from a phase III trial of Traumakine earlier this year scientists have discovered that patients with a particular type of genetic mutation - called a C/T mutation - were almost six times more likely to survive than those who were also taking the drug but didn’t have the mutation

Faron will now liaise with European and US regulators to figure out the next best step for the drug.

[oldnotwise] 30/1/2019 10:34

I see Gunthorpe's back on LSE...
I think I rather like his style of posting... Lighthearted and succinct! :-)
ATB

[panama7] 30/1/2019 09:40

I note a couple of Posters on LSE have received emails from Holloway and Goodfellow stating that the SCIB1 Combi trial is on track to commence in H1. The trial was on track to start last year until the IND was rejected 4 months ago so how can it be on track now without an IND. What a totally misleading bunch our BOD are and not for the first time.

[supernumerary] 30/1/2019 01:11

Yes - you can imagine "you live, you pay - you die, you don't" becoming the medical equivalent of legal 'no win no fee' arrangements. It's eminently logical but putting a price on humanity is always going to be controversial, to say the least.

I was thinking more of personalised medicines - the CAR-Ts and gene editing therapies for instance - where cost is likely to be an issue for decades to come. It's instructive to consider a boundary case such as Stephen Hawking for example: the cost of lifelong treatment vs his achievements - major advances in the most fundamental science.

He certainly wouldn't have had insurance, so in such a case the state would have to make the calculation of net benefit. Most would I think agree that in his case it was a wise investment, but for the weak, or elderly, or refugee, or intellectually limited, or whatever? Huge issues to be confronted.

Up to now these possibilities have been the province of science fiction, but it seems the FDA has just pressed 'Fast Forward'...

[tosh123] 29/1/2019 17:00

Even your heir apparent ( love child Ray )is now taking exception and arguing with your uneducated nonsense and lies.
You're losing your touch and your influence.
There are people on both forums that know far more than you do, and they prove it time after time, so give up trying to impose yourself, your credibility is now shot to pieces, and the best thing about that, is that you did it all by yourself.
Your desperate attempts to feel and sound important have backfired, people are now seeing for themselves, what a loser you really are.
You've self imploded.
Brilliant.

[panama7] 29/1/2019 16:41

Are you saying your keyboard got stuck and you only meant to sell one lot of 50k and ended up selling 10 lots.

[inanaco] 29/1/2019 16:36

hxxps://www.nexexchange.com/member?securityid=1268529

key board stuck ?

not on the Real NEX site

[panama7] 29/1/2019 16:33

The NEX Exchange is showing 10 x 50,000 0f sales at 11:38. Any views anyone, that is half a million at the lowest price for 6 years.

[tosh123] 29/1/2019 14:59

This is just brilliant !
The idiots latest offering is absolutely priceless, and i quote ;-

"what does that mean .... Mr Ruck QC the man who is underwater in scancell and for some unknown reason is determined to undermine "

I cant stop laughing at the bloke.
The bloke that bought at 45p,and numerous other levels, far above the current 7.5p, has the audacity to point a finger at someone else who he accuses and attempts to ridicule for being " underwater " ... tears are rolling down my cheek.

Furthermore, the self professed and self advertised " professor ", also tries to undermine RR by labelling him a QC... you honestly cant make this stuff up.

Come on LSE posters, in this one post, you have all the proof that you need... the guy is totally bonkers...he's raving mad ... he is so desperate that he resorts to posts like this.
How can you take him seriously ?

[oldnotwise] 29/1/2019 11:58

I guess the only positive spin that can be put forward is that Data from trials will evidence the proof of the pudding.
If that data is a s good as can be hoped for then I suspect that will be the catalyst for the resurgence we all hope for.
Obviously any commercial deal will assist, but that seems to be unlikley until more "Saleable" data is forthcoming, since we know that the released data to date (however compelling) has been isufficient for our (SP oriented) needs.
So as long as the company can keep liquid without a need for cash calls at this level, maybe, just maybe we can continue quietly.
Should there be no deal or compelling data in the near future, we may be looking a little less optimistically hopeful by early 2020.
So, as ever, Let's wait in hope for the "Trigger"...
Sure Delboy, "This time next year we'll be Miwlionaires"..
Fingers crossed :-)
AIMO
ATB